TFR patients exhibited distinct enrichment in complement and coagulation cascades (C3, C4B, F9, F11) and metabolic pathways.<h4>Discussion</h4>Plasma EV proteomes reflect CML clinical status, revealing immune and cytoskeletal alterations associated with treatment response, remission, and resistance, suggesting potential biomarkers for disease monitoring. The gene discussed is TFRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.